Regulatory Open Forum

 View Only
  • 1.  IND Amendment

    This message was posted by a user wishing to remain anonymous
    Posted 18-Oct-2021 15:00
    This message was posted by a user wishing to remain anonymous

    Once an IND Amendment is submitted what is the usual turn around time for the agency. Also, how do the agency communicate (email/ mail) to tell the sponsor if the technical contents are approved or some deficiencies need to be corrected. 

    Thank you in advance.


  • 2.  RE: IND Amendment

    Posted 18-Oct-2021 15:09
    Hello,

    The only IND submissions for which there is a formal response/review time for FDA is for a new IND (30 days), or for FTD/BTD/RMAT/SPA (60 days).  It is undefined for all other IND amendments including CMC amendments, NC & C info amendments, etc.  In most cases there is no need to follow up to ask if it is ok to proceed.  However, for significant CMC amendments, I usually allow for 30 days then call/email the FDA PM if I do not hear anything in this period of time.  They won't spontaneously tell you it is ok to proceed but they will get in touch if they have serious concerns or objections, either via phone or via email,  

    There are no good rules to follow on this, but it never hurts to call/email the PM if you have questions or want to know if FDA does not want the sponsor to implement the change. 

    Best Regards,



    ------------------------------
    Charlene Revel
    Associate Director, Regulatory Science
    Cambridge MA
    United States
    ------------------------------



  • 3.  RE: IND Amendment

    Posted 19-Oct-2021 06:26
    Hello,
    in addition to Charlene's response, maybe the MAPP 6030.9 is also helpful to your question: Good Review Practice: Good Review Management Principles and Practices for Effective IND Development and Review (fda.gov)
    Section 4.3 includes a table with review goals and type of communication with sponsor for various IND amendments.

    Hope that helps!
    Beate

    ------------------------------
    Beate Schmidt RAC, MSc
    Consultant Regulatory Affairs
    Mannheim
    Germany
    ------------------------------



  • 4.  RE: IND Amendment

    This message was posted by a user wishing to remain anonymous
    Posted 21-Oct-2021 22:48
    This message was posted by a user wishing to remain anonymous

    Thank you so much for your response


  • 5.  RE: IND Amendment

    Posted 20-Oct-2021 00:23
    Hello
    Charlene /Beate had given a nice explanation to your query, to add on further a quick reference
    https://www.fda.gov/drugs/investigational-new-drug-ind-application/ind-application-reporting-information-amendments
    FDA would contact the sponsor if the amendments can have serious concerns,  or else you can also contact the RPM

    ------------------------------
    Pallavi Sharma
    Florham Park NJ
    United States
    ------------------------------